In summary, our research found a new molecule, NXPH4, which influences the prognosis of patients with bladder cancer, and revealed that NXPH4 promotes progression, metastasis, and gemcitabine resistance in bladder cancer by enhancing glycolysis through modulating the expression of NDUFA4L2. Here, COXFA4L2 is linked to urinary bladder carcinoma.